Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMLI + Cyclophosphamide + Etoposide Conditioning for Allogeneic HSCT in High-Risk MDS/AML
2024-514484-25-00Phase 2Authorised
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and etoposide in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoints: Toxicity and 2-year progression-free survival (PFS). Planned start Nov 2024; status: authorised.
02
Drugs
cyclophosphamideetoposide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-514484-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514484-25-00.